Look ahead
in your
psoriasis journey
A clinical study of a novel
drug for moderate-severe psoriasis.
Plaque psoriasis causes itchy, dry, scaly skin for up to 3.5% of people around the world.
In many cases the negative impact on a person’s quality of life is severe.
Today’s treatments don’t do enough, and doctors are searching for new ways to help.
This study is to evaluate a novel approach, given in the form of a pill, to see if it can
improve medical treatment of plaque psoriasis.
Who can participate
Participating in a study is an important decision, and may help doctors
change psoriasis treatment.
You may be eligible if you:
– have moderate-severe plaque psoriasis
– are 18 years of age or older
– have plaques covering 10% or more of your body.
Participants must have a diagnosis of plaque psoriasis, and be willing
to attend clinic visits to answer questions about their health.
There are more criteria for participation and only study staff can
determine if you qualify to enroll.
While participating in the study you will receive care from doctors who
specialize in psoriasis.
Condition
Plaque Psoriasis
Age
18+
Delivery Method
Oral
What to expect during the study
You will attend a screening 28 days before the study to evaluate your health and
be sure you are a good fit for the trial.
Participants will be assigned by chance to one of three groups:
• The first group will receive the active study drug.
• The second group will take a placebo, with the option to switch to the study drug
. after 16 weeks.
• The third group will take an existing treatment.
After 16 weeks, participants in the placebo group will switch to the active study drug.
At 24 weeks, eligible participants can choose to enter an extension study to continue treatment with the study drug.
Study Length
About 6 months (with possible extension)
Number of Doses
Twice daily for 24 weeks.
Cost to Participate
There is no cost.
About the study drug
The study drug is a small molecule inhibitor that targets a relatively new immune system signal pathway. This is a Phase 3 trial, which means the study drug has already been through two levels of previous clinical studies in humans.
It is hoped that it can lead to greater skin clearance with less side-effects than currently approved options for moderate-severe plaque psoriasis.
Potential benefits and risks
Before participating in the study, we will discuss informed consent with you. This is to make sure that you fully understand all of the risks and benefits. After the discussion you may give your informed consent.
Participants may see improvement, worsening, or no change in their symptoms, or could have a reaction to the study drug.
The most common potential side effects are headaches and an increased risk of infection.
Trial Application Form
You can call us at #(289)-763-8666 to discuss this trial.